Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139


Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.

Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A.

Eur J Endocrinol. 2014 Feb 7;170(3):451-9. doi: 10.1530/EJE-13-0797. Print 2014 Mar.


Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.

Jensterle M, Kravos NA, Goričar K, Janez A.

BMC Endocr Disord. 2017 Jan 31;17(1):5. doi: 10.1186/s12902-017-0155-9.


Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.

Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E.

Eur J Endocrinol. 2018 Jul;179(1):1-11. doi: 10.1530/EJE-18-0175. Epub 2018 Apr 27.


Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.

Ferjan S, Janez A, Jensterle M.

Metab Syndr Relat Disord. 2017 Dec;15(10):515-520. doi: 10.1089/met.2017.0095. Epub 2017 Oct 24.


Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.

Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A.

Endocr Res. 2015;40(3):133-8. doi: 10.3109/07435800.2014.966385. Epub 2014 Oct 20.


Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.

Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E, Mullington J, Maratos-Flier E.

Diabetes Care. 2012 Jan;35(1):4-11. doi: 10.2337/dc11-0931. Epub 2011 Oct 31.


GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.

Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jørgensen NR, Jensen JE, Holst JJ, Madsbad S, Torekov SS.

J Clin Endocrinol Metab. 2015 Aug;100(8):2909-17. doi: 10.1210/jc.2015-1176. Epub 2015 Jun 4.


Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.

Jensterle M, Kocjan T, Janez A.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1476-81. doi: 10.1210/jc.2014-1430. Epub 2014 May 13.


Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.

Jensterle M, Pirš B, Goričar K, Dolžan V, Janež A.

Eur J Clin Pharmacol. 2015 Jul;71(7):817-24. doi: 10.1007/s00228-015-1868-1. Epub 2015 May 21.


A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).

Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, Rana A, Zinman B; BEGIN: VICTOZA ADD-ON (NN1250-3948) study group.

Diabetes Obes Metab. 2014 Jul;16(7):636-44. doi: 10.1111/dom.12262. Epub 2014 Feb 11.


Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.

Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR.

Diabetes Obes Metab. 2013 Mar;15(3):204-12. doi: 10.1111/dom.12012. Epub 2012 Oct 11. Review.


Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.

Feng P, Yu DM, Chen LM, Chang BC, Ji QD, Li SY, Zhu M, Ding SH, Zhang BZ, Wang SL, Li HT, Lin JN, Wang MJ, Guo JC, Liu J, Liu ZD, Wu ST, Yang JH.

Acta Pharmacol Sin. 2015 Feb;36(2):200-8. doi: 10.1038/aps.2014.136. Epub 2015 Jan 26.


A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.

Brady EM, Davies MJ, Gray LJ, Saeed MA, Smith D, Hanif W, Khunti K.

Diabetes Obes Metab. 2014 Jun;16(6):527-36. doi: 10.1111/dom.12249. Epub 2014 Jan 26.


Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.

Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ; LEAD-2 and LEAD-3 Study Groups.

Diabetes Obes Metab. 2009 Dec;11(12):1163-72. doi: 10.1111/j.1463-1326.2009.01158.x.


Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.

Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, Van Gaal L, Astrup A; NN8022-1807 Investigators.

Int J Obes (Lond). 2014 May;38(5):689-97. doi: 10.1038/ijo.2013.149. Epub 2013 Aug 14.


The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study.

Rasmussen CB, Lindenberg S.

Front Endocrinol (Lausanne). 2014 Aug 27;5:140. doi: 10.3389/fendo.2014.00140. eCollection 2014.

Supplemental Content

Support Center